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Recombinant human T-cell leukemia virus type II (HTLV-II) envelope external glycoprotein, gp46-II, was expressed using
a vaccinia virus vector. A recombinant gp46-II fused to an epitope of the influenza virus hemagglutinin, YPYDVPDYA, was
purified by immunoaffinity chromatography. The purified glycoprotein was used to immunize Balb/c mice, and antibodies
against gp46-II were detected by Western blot analysis and syncytium inhibition assays. We transformed spleen cells from
the immunized mice by retroviral infection with ABL-MYC (C2) and intraperitoneally transplanted the infected cells into
syngeneic Balb/c and severe combined immunodeficient (SCID) mice. The plasmacytomas established ascitic tumors that
produced antibodies directed against HTLV-II gp46-II. Ascites developed more rapidly in SCID mice than in normal syngeneic
mice. This procedure provides a general means to generate antibodies rapidly. q 1995 Academic Press, Inc.
Human T-cell leukemia virus type II (HTLV-II) has been sera confirmed the expression of this protein (Fig. 1(I))
associated with malignancies such as hairy-cell leukemia in the cytoplasmic fraction of vDK12-infected CV1 cells.
(8), and more recently, it has also been reported to be Figure 1(I) shows that the gp46-II band with an apparent
associated with myelopathy (1, 7, 14). HTLV-II infection is molecular weight of 50 kilodaltons (kDa) is not reactive
present among some indigenous populations and intrave- to serum from an uninfected individual and is not de-
nous drug users in the United States (10, 12, 13). The tected in vDK7-infected cells (a recombinant vaccinia vi-
mechanism by which HTLV-II induces malignancy is not rus expressing the Escherichia coli lacZ gene). (The
clearly understood; however, it immortalizes T-cells in vitro background bands in this Western blot are attributed to
(4). The env gene of HTLV plays a crucial role in the life- human anti-vaccinia antibodies present in the serum
cycle of the virus, and may be directly relevant to in vitro from an uninfected individual.) Although this recombinant
T-cell transformation and in vivo disease processes in- glycoprotein contains the original signal sequence, the
duced by HTLV. The env gene of HTLV-II encodes one majority of the protein was not secreted, since it was not
glycoprotein precursor, gp61-II, present in infected cells, detectable in the culture media by either Western blot
which is processed to yield the external glycoprotein, or immunoprecipitation assays (not shown). This is in
gp46-II, and the transmembrane protein, gp21, present on contrast to the secretory properties of external proteins
infected cells and the mature virions (16). of other retroviruses such as HIV gp120 (5).
In this report, we describe a method which allowed To facilitate purification of cell-associated gp46-II, we
us to effectively generate purified recombinant HTLV-II engineered a recombinant gp46-II fusion protein con-
envelope and envelope-specific antibodies. This method taining a YPYDVPDYA peptide at its C-terminus. YPYDVP-
is also generally applicable to other antigens. DYA is an epitope from the influenza virus hemagglutinin
Recombinant vaccinia virus (vDK12) expressing the ex- and is efficiently recognized by a monoclonal antibody,
ternal envelope protein, gp46-II, was generated by using 12CA5 (18). This epitope-tagged gp46-II recombinant
the pSC11 vector (2). Immunoprecipitation (not shown) vaccinia virus, vGP46-II-YPYDVPDYA, was constructed
and Western blot assays using HTLV-II-positive human using a vaccinia recombination vector, pTM3 (6, 11). Fig-
ure 1(II) shows Western blot analysis of the recombinant
external glycoprotein, gp46-II-YPYDVPDYA (Fig. 1(II, lane
1 Present address: Myles H. Thaler Center for AIDS and Human B)), in the virus-infected cells, which was detected in
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patient sera and 12CA5, a monoclonal antibody.Virginia, Charlottesville, VA 22908.
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FIG. 1. Expression and purification of recombinant gp46-II glycoproteins. The HTLV-II gp46 DNA sequence from plasmid pH6neo, which encodes
a full-length HTLV-II genome (3), was cloned into appropriate vaccinia recombination vectors. Vaccinia viruses expressing HTLV-II glycoproteins
were generated by recombination (2). CV1 cells were infected with these recombinant vaccinia viruses (m.o.i.  1). Forty-eight hours postinfection,
the cells were washed with phosphate-buffered saline (PBS) and treated with PBS-EDTA (1 mM) for harvesting. The cells were then lysed with cell
lysis buffer (10 mM Tris, pH 8.0, 150 mM NaCl and 1.5 mM MgCl2 , 1% NP-40). The soluble fractions were separated by 10% SDS–PAGE, followed
by Western blot analysis (Western blot AP system, Promega, Madison, WI) with various antibodies, as indicated. I and II show Western blot analysis
of recombinant gp46-II. (I) vDK12-infected CV1 cells. vDK7 is a recombinant virus expressing the E. coli lacZ protein and is used as a negative
control. Control serum is from an HTLV-II-uninfected individual. (II) vGP46-II-YPYDVPDYA- and vTF7-3-infected cells. vTF7-3 is a recombinant vaccinia
virus expressing phage T-7 RNA polymerase, and 12CA5 is a monoclonal antibody that recognizes YPYDVPDYA. (Lane A) cells infected with vTF7-
3 as negative controls. (Lane B) cells co-infected with vTF7-3 and vGP46-II-YPYDVPDYA viruses. (III) Immunoaffinity chromatography purification of
gp46-II-YPYDVPDYA using 12CA5 monoclonal antibodies. For preparation of 12CA5 monoclonal antibodies, 5 1 106 12CA5 hybridoma cells were
injected intraperitoneally into a SCID mouse that had been pristine-primed 6 days prior to cell injection with 0.5 ml of 2-, 6-, 19-, and 14-
tetramethylpentadecase (Sigma, St. Louis, MO). Approximately 10 days postinjection, ascitic tumors were formed. Ascitic fluid was harvested, and
the cell-free fraction was prepared as antibody stock by centrifugation to remove cells and cell debris. For preparation of the affinity column, the
antibodies in the ascites fluid supernatant were purified and immobilized onto protein A agarose (ImmunoPure Plus Immobilized Protein A, Pierce,
Rockford, IL) as described by Schneider et al. (15). Briefly, 5 ml of ascites fluid (12CA5:Ig2b) was diluted fourfold with Pierce’s ImmunoPure IgG
binding buffer and incubated with 2 ml protein A (Pierce) agarose beads by rocking for 1 hr at room temperature. The unbound proteins were
rinsed away from the beads three times with the same buffer, and the bound antibodies were cross-linked to the bead. This was achieved by
washing the bead with 0.2 M thriethanolamine, pH 8.2, and resuspension in 40 ml of 20 mM dimethylpimelimidate dihydrochloride freshly made in
0.2 M thriethanolamine. The mixture was then agitated at room temperature for another hour. The cross-linking reaction was stopped by spinning
down the beads, followed by resuspension in 20 mM ethanolamine, pH 8.2. Five minutes later, the cross-linked beads were washed three times
with 0.1 M borate buffer, pH 8.2.
Approximately 2 1 108 CV1 cells (in 10 T-175 flasks) were coinfected with vTF7-3 and vGP46-II-YPYDVPDYA and treated as described above.
Five milliliters of solubilized proteins were incubated with 1 ml of 12CA5 monoclonal antibody-coated beads by rocking overnight at 47. The beads
were loaded onto Bio-Rad 7-ml plastic columns, and the columns washed with 10 vol of PBS–0.5 M NaCl at 47, followed by washing with 2 vol of
the same buffer plus 0.5% octyl-glucoside and 1 vol of PBS–0.5 M NaCl. The protein was eluted with 0.1 M glycine, pH 2.5, and the fractions (0.5
ml) were collected. The eluted samples were analyzed by silver staining (Rapid Ag Stain, ICN Radiochemicals, Irvine, CA). Lane 1, starting cell
lysate from vTF7-3-infected CV1 cells; Lane 2, starting cell lysate from vTF7-3/vGP46-II-YPYVPDYA-coinfected CV1 cells; Lane 3, flow-through of
12CA5 column from vTF7-3-infected CV1 cells; Lane 4, flow-through of 12CA5 column from vTF7-3/vGP46-II-YPYDVPDYA-coinfected CV1 cells; Lane
5, eluant (5 ml) from 12CA5 column of vTF7-3-infected CV1 cells; Lane 6, eluant (5 ml) from 12CA5 column of vTF7-3/vGP46-II-YPYVDPDYA-coinfected
CV1 cells; Lane 7, eluant (15 ml) from 12CA5 column of vTF7-3 infected CV1 cells; Lane 8, eluant (15 ml) from 12CA5 column of vTF7-3/vGP46-II-
YPYDVPDYA-coinfected CV1 cells; Lane 9, 100 ng pure CKS fusion protein, a bacteria fusion protein that encodes one-third of the gp46-II C-terminal
(kindly provided by Abbott Laboratories and used as a quantitation control in silver staining); and Lane 10, 33 ng pure CKS fusion protein.
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monoclonal antibodies was prepared as described by immunodeficiency would allow more rapid growth of ex-
ogenous tumors and would not contribute endogenousSchneider et al. (15) and used to purify HTLV-II gp46-II-
YPYDVPDYA. This procedure purifies gp46-II-YPYDVP- immunoglobulins to the ascitic fluid; therefore, all the
antibodies in the transplanted mice would be producedDYA to near homogeneity in a single-step procedure, as
shown by silver staining (Fig. 1(III)) and confirmed by from ascites tumor cells. All animals (four SCID and four
Balb/c mice for each of the two gp46-immunized mouseWestern blot analysis (not shown). Starting with 14 mg
of cytoplasmic lysate (from 2 1 108 cells coinfected with spleens (see above)) inoculated with transformed spleen
cells developed ascites tumors. Five to fifteen millilitersvTF7-3 and vGP46-II-YPYDVPDYA at an multiplicity of in-
fection (m.o.i.) of 1), 5 mg of purified gp46-II-YPYDVPDYA of ascites fluid was harvested, and the cell-free superna-
tant fraction of the fluid was tested for antibodies againstwas obtained.
We tested the antigenicity of our recombinant gp46- the external glycoprotein, gp46-II. Every animal produced
gp46-II-specific antibodies, as demonstrated by eitherII. Four Balb/c mice were immunized by intraperitoneal
injection with 1 mg of purified gp46-II-YPYDVPDYA, with Western blot analysis (examples are shown in Fig. 2(III))
or an immunoprecipitation assay (data not shown). Thetwo subsequent boosts with the same amount of protein
at 2-week intervals. Blood samples were collected by tail antibodies from ascites such as SB1 showed titers com-
parable to those of immunized mouse sera since theybleeds after two boosts. The sera were tested by Western
blot assay for antibodies against gp46-II-YPYDVPDYA both demonstrated similar intensities of the specific band
in Western blot at equivalent dilutions (data not shown).and untagged gp46-II expressed in vDK12, and the re-
sults are shown in Fig. 2(I). These results indicate that Importantly, as we predicted, these antibody-producing
ascites tumors developed faster in SCID mice (within 2all the mice produced antibodies against the original
gp46-II-YPYDVPDYA and gp46-II from vDK12, as well as to 4 weeks) than in syngeneic Balb/c mice (4 to 6 weeks).
It was noteworthy that the ascites from SCID mice gener-from other sources (not shown), demonstrating that gp46-
II-YPYDVPDYA is able to elicit a humoral response ally showed greater specificity than Balb/c ascites, with
less background in Western blots, probably due to theagainst the HTLV-II envelope protein. Furthermore, anti-
sera from these immunized mice was also able to inhibit lack of endogenous antibodies produced in SCID.
Among the antibodies generated from different recipi-cell fusion mediated by full-length HTLV-II envelope gly-
coprotein, as shown in Fig. 2(II). ent animals, SB1 was shown to react to the central por-
tion of gp46-II in both Western blots and immunoprecipi-Weissinger et al. (17) previously described an alterna-
tive approach to generate antibodies, in which immu- tation assays using chimeric gp46-I/II (data not shown),
but had no cross-reactivity to the recombinant HTLV-Inized Balb/c mice were infected with a replication-defec-
tive recombinant murine leukemia virus, ABL-MYC, ex- external protein, gp46-I (data not shown). Recombinant
gp61-II was purified by immunoaffinity chromatographypressing the v-abl and c-myc genes. The majority of the
target cells transformed in vivo by viral infection with or using the SB1 antibody (data not shown). Another two
ascites antibodies originally from the second immunizedwithout helper virus are plasma cells (9), which form
ascites tumors. The tumor cells can also be established mouse, SFO and SEO, were shown by Western blot anal-
ysis to not only react with HTLV-II gp46, but also to cross-in syngeneic recipient mice by intraperitoneal injection.
The plasmacytoma ascites tumors produce specific anti- react with recombinant HTLV-I gp46 (Q.-X. Li, unpub-
lished observation) at a similar dilution (1:100) (data notbodies. This procedure takes advantage of the fact that
retroviruses only infect the actively dividing plasma cells, shown). The clonality of these tumors remains to be de-
termined. SB1, SEO, and SFO are all IgG antibodies, asand abl/myc oncogenes together synergistically trans-
form plasma cells (9). This selective transformation of determined by ELISA assay. Further cloning of these tu-
mor cells would be necessary to generate monoclonalplasma cells provides an efficient approach to generate
antibody-producing cell lines. antibodies.
There are two conventional means to generate anti-We used a modified version of this published proce-
dure to prepare antibodies against HTLV-II gp46 by in bodies against a specific protein. One is to immunize
large animals (e.g., rabbits) with the antigens and obtainvitro retroviral infection instead of in vivo infection, since
this was shown to be more efficient in transforming the polyclonal antibodies from the animals’ sera, which
usually requires milligram quantities of antigens. Theplasma cells (D. Largaespada, personal communication).
Spleen cells from two mice immunized with purified other way is to immunize small animals (e.g., mice) and
use the immunized spleen cells to fuse with myelomagp46-II-YPYDVPDYA were infected in vitro with ABL-MYC
(C2) helper-free viruses. The infected cells were inocu- cells; the resulting antibody-producing hybridoma cells
are used to produce antibodies. However, the procedurelated intraperitoneally into syngeneic Balb/c or severe
combined immunodeficient (SCID) mice to generate plas- to screen for antibody-producing hybridoma cells is la-
bor-intensive. We chose an alternative procedure of us-macytomas in the form of ascites tumors. The SCID mice
were also tested because we expected that its combined ing the Abl-Myc transformation for three reasons: (1) it
/ m4655$7644 11-21-95 06:21:04 viras AP-Virology
683SHORT COMMUNICATION
FIG. 2. Generation of gp46-II-specific antibodies. Humoral immune response to gp46-II-YPYDVPDYA in mice. One microgram of purified protein
in 0.5 ml of neutralized (by Tris) elution buffer was mixed with 0.5-ml adjuvants and injected intraperitoneally into 7- to 8-week-old Balb/c mice
three times at 2-week intervals. The first injection was with Freund’s complete adjuvant (Gibco-BRL, Grand Island, NY), the second with Freund’s
incomplete adjuvant, and the third with PBS. Four days after the third injection, sera were prepared from blood (obtained by tail bleeding) and
tested for anti-gp46-II activity (1:100 dilution). (I) Western blot analysis of gp46-II-YPYDVPDYA-immunized mouse sera. Lane A, CV1 cells coinfected
with vGP46-II-YPYVPDYA viruses and vTF7-3; and Lane B, cells infected with vDK12. (II) Syncytium inhibition analysis by sera from purified gp46-
II-YPYDVPDYA-immunized mice. Confluent HeLa cells growing in 24-well plates were infected with vDK11 virus (m.o.i.  0.1), a recombinant vaccinia
virus expressing full-length HTLV-II envelope protein. Three hours postinfection, antisera were added to the culture at a dilution of 1:100, and 10
hr postinfection, cultures were examined for syncytium formation. (A) Serum from an unimmunized mouse; (B) sera from mice immunized with gp46-
II-YPYDVPDYA; and (C) HTLV-II patient sera. (III) Antibodies specifically reactive to gp46-II generated by an Abl-Myc (C2) MuLV-transformed
plasmacytoma. The mice immunized three times, as in (I), were immunized one more time with 1 mg purified gp46-II-YPYDVPDYA in PBS 2 weeks
after the third immunization. Four days after the fourth immunization, the mice were sacrificed, and single-cell suspensions were prepared from
their spleens. Red blood cells were removed by an RBC lysis reagent (Sigma, St. Louis, MO). The single-cell suspensions were washed with PBS
and counted. ABL-MYC (C2) helper-free viral stock was prepared as described (9). Briefly, ABL-MYC (C2) cells were cultured in T-175 flasks in
DMEM with 10% calf serum. When cells reached 50% confluency, the medium was replaced with 10 ml of the same fresh medium. Twenty-four
hours later, the media was harvested and spun to remove cells and debris. Spleen cells (5 1 107) were incubated with 50 ml of freshly prepared
viral stocks (106 foci-forming units (FFU)/ml) in the presence of polybrene (10 m/ml) for 4 hr at 377. The infected cells were washed with DMEM
medium and inoculated with 5 1 106 cells in 0.5 ml PBS intraperitoneally into pristane-primed (described in legends of I–III) Balb/c or SCID mice
to generate plasmacytomas in the form of ascites tumors. Within 2 to 4 weeks in SCID mice, and within 4 to 6 weeks in Balb/c mice, ascites tumors
developed. Cell-free ascites fluid was prepared (see legends of I–III) and tested by Western blot analysis for anti-gp46-II antibody activity. The
ascites fluid was diluted at 1:100 for staining. The ascites originally resulting from the first immunized mouse are shown in this figure. Names begin
with ‘‘S’’ are the acites from SCID mice and the names begin with ‘‘A,’’ ‘‘B,’’ . . . are ascites from Balb/c mice. Lane A, cells coinfected with vTF7-3
and vGP46-II-YPYDVPDYA viruses; and Lane B, cells infected with vDK12.
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